The fast decrease in cost-per-base drove the broad adoption of next-gen sequencing. We see a similar trend in proteomics, where the equivalent measure is the cost per relevant data point. Today we can analyze ten times more relevant features within the proteome than we could ten years ago, and we expect even greater leaps forward in 2022 and beyond. Read more about what our CEO, Oliver Rinner, thinks about the future of proteomics.

This year, we highlighted how advances in our workflows and analytical platforms enable deeper insights into the plasma proteome and support biomarker discovery. Not only are we pushing the boundaries of how many different proteins we can detect in plasma. Biognosys’ CTO explains how we can deliver high-throughput in-depth analysis at scale and also support research from early-stage to clinical studies.

We are excited to share the latest co-publication with our collaboration partners at AstraZeneca. Protein structural alterations and steric hindrances lead to unique cleavage site accessibility that allows LiP-MS to use the entire potential target space to determine unbiased peptide components that drive positive target identification. This publication shows how LiP-MS permits target identification, binding affinity estimation, and binding site localization of kinase inhibitors.

A new agreement leverages Biognosys and Thermo Fisher Scientific's complementary capabilities in mass spectrometry-based proteomics. Biognosys deploys their instruments in its state-of-the-art facility for contract research services. Thermo Fisher Scientific co-markets Biognosys software and kits with its Thermo Scientific™ instruments and workflows.

Mass spectrometry based proteomics is fueling advances for plasma biomarker discovery and unlocking a new era of precision medicine. Find out why in this piece published on GenomeWeb.